Hepatocellular Carcinoma Medical Services in China

Hepatocellular carcinoma (HCC), the most common primary liver malignancy, typically arises in the setting of chronic liver disease—especially cirrhosis secondary to hepatitis B or C infection, alcohol-related liver disease, or non-alcoholic steatohepatitis (NASH). Early-stage HCC may be asymptomatic; diagnosis relies on imaging (contrast-enhanced CT or MRI) and serum alpha-fetoprotein (AFP) assessment. Treatment strategy is stage-dependent: surgical resection or liver transplantation remains curative for eligible patients, while locoregional therapies—including transarterial chemoembolization (TACE), radiofrequency ablation (RFA), and stereotactic body radiation therapy (SBRT)—are standard for intermediate-stage disease. Systemic therapy with tyrosine kinase inhibitors (e.g., sorafenib, lenvatinib) or immune checkpoint inhibitors (e.g., atezolizumab + bevacizumab) has significantly improved survival in advanced cases.

China offers distinct advantages for international HCC patients: its tertiary hospitals—many accredited by JCI or ISO—house world-class hepatobiliary oncology teams with extensive experience in complex hepatectomies and living-donor liver transplantation. Cutting-edge technologies such as real-time intraoperative ultrasound-guided ablation, robotic-assisted surgery, and next-generation sequencing–guided molecular profiling are widely deployed. Clinical outcomes align with global benchmarks: five-year survival after resection exceeds 60% in early-stage cohorts, and multidisciplinary tumor boards ensure personalized, evidence-based care. Crucially, treatment costs in China are typically 40–60% lower than in the US or Western Europe—without compromising quality—making comprehensive care financially accessible.

As a dedicated medical tourism agency, we facilitate seamless access to these resources: vetting top-tier hospitals, coordinating appointments with specialist hepatobiliary oncologists, clarifying all-inclusive pricing upfront, and providing end-to-end support—from visa assistance and medical translation to post-treatment follow-up coordination.

Treatment Options & Itemized Cost Breakdown: Hepatocellular Carcinoma (HCC)

Non-Surgical / Conservative / Medication Options

*Indicated for unresectable, advanced, or palliative-stage HCC; requires Child-Pugh A/B liver function and ECOG 0–2.*

• •Systemic Therapy (1st-line)

- Lenvatinib (12 mg/day): ¥12,600/month → $1,760 - Atezolizumab + Bevacizumab (IV q3w): ¥28,500/cycle → $3,980

• •Supportive & Monitoring Costs

- Abdominal MRI (contrast-enhanced, every 3 months): ¥2,800 → $390 - CT-guided biopsy (if diagnosis uncertain): ¥1,600 → $225

Surgical / Procedural / Interventional Options

*Eligibility: Single tumor ≤5 cm or ≤3 tumors each ≤3 cm; no macrovascular invasion; Child-Pugh A; MELD score <10.*

• •Liver Resection (Open/Laparoscopic)

- Preoperative workup (CT/MRI + ECG + pulmonary function + coagulation panel): ¥3,100 → $435

• •Transarterial Chemoembolization (TACE)

- Drug-eluting bead TACE (DEB-TACE): ¥26,000/session → $3,630

• •Radiofrequency Ablation (RFA) / Microwave Ablation (MWA)

- Includes ultrasound/CT guidance and anesthesia

Special / Complex Condition Options

• •Bridge-to-Transplant (for waitlisted patients)

• •Portal Vein Tumor Thrombus (PVTT)

• •Child-Pugh B/C or decompensated cirrhosis

Quick Selection Guide

• •Early-stage, fit patient (<70 y, no comorbidities): Resection — highest 5-year survival (60–70%), cost-effective long-term.
• •Intermediate-stage (multinodular, preserved liver function): TACE — median OS 20–25 months; optimal balance of efficacy and affordability ($2,590/session).
• •Advanced-stage (extrahepatic spread, ECOG 1–2): Atezolizumab + Bevacizumab — superior OS vs. sorafenib; justified despite higher monthly cost ($3,980/cycle) due to response durability.
• •Elderly (>75 y) or frail with comorbidities: Lenvatinib monotherapy — oral convenience, lower toxicity burden ($1,760/month), avoids procedural risks.
• •Child-Pugh B cirrhosis with small tumor: MWA under ultrasound guidance — minimally invasive, preserves hepatic reserve ($1,790–$2,120).